Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials-Reference-Cited by-同舟云学术

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

Published:2021-05-28 Issue:5 Volume:36 Page:244-250
ISSN:0268-1315
Container-title:International Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Kane John M,Durgam Suresh,Satlin Andrew,Vanover Kimberly E,Chen Richard,Davis Robert,Mates Sharon

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference19 articles.

1. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.;Achtyes;BMC Psychiatry,2018

2. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation.;Briggs;Health Qual Life Outcomes,2008

3. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial.;Correll;JAMA Psychiatry,2020

4. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.;Correll;World Psychiatry,2015

5. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.;Correll;World Psychiatry,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications;European Journal of Medicinal Chemistry;2024-11

2. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review;Expert Opinion on Drug Safety;2024-09-03

3. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-09

4. Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia;Expert Opinion on Drug Safety;2024-03-25

5. Challenges, unmet needs and future directions – a critical evaluation of the clinical trial landscape in schizophrenia research;Expert Review of Clinical Pharmacology;2023-12-18